News >

Cytoreductive Nephrectomy in mRCC Paradigm Requires Careful Patient Selection

Jessica Hergert
Published: Wednesday, Nov 13, 2019

Erik P. Castle, MD, a professor of urology at Mayo Clinic

Erik P. Castle, MD

The metastatic renal cell carcinoma (mRCC) paradigm has evolved with a multitude of systemic therapies and pivotal data in recent years, challenging the role of cytoreductive nephrectomy, said Erik P. Castle, MD. However, he added, the approach can still be utilized in select patients.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication